AQS Stock Overview
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Aequus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.06 |
| 52 Week Low | CA$0.01 |
| Beta | 0.29 |
| 1 Month Change | 0% |
| 3 Month Change | -40.00% |
| 1 Year Change | -50.00% |
| 3 Year Change | -92.31% |
| 5 Year Change | -92.50% |
| Change since IPO | -97.86% |
Recent News & Updates
Shareholder Returns
| AQS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -2.1% |
| 1Y | -50.0% | 58.0% | 3.6% |
Return vs Industry: AQS underperformed the Canadian Pharmaceuticals industry which returned 46% over the past year.
Return vs Market: AQS underperformed the Canadian Market which returned 3.2% over the past year.
Price Volatility
| AQS volatility | |
|---|---|
| AQS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 14.2% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: AQS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AQS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 12 | Doug Janzen | www.aequuspharma.ca |
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Aequus Pharmaceuticals Inc. Fundamentals Summary
| AQS fundamental statistics | |
|---|---|
| Market cap | CA$1.99m |
| Earnings (TTM) | -CA$3.27m |
| Revenue (TTM) | CA$587.09k |
3.4x
P/S Ratio-0.6x
P/E RatioIs AQS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AQS income statement (TTM) | |
|---|---|
| Revenue | CA$587.09k |
| Cost of Revenue | CA$152.43k |
| Gross Profit | CA$434.66k |
| Other Expenses | CA$3.70m |
| Earnings | -CA$3.27m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 74.04% |
| Net Profit Margin | -556.88% |
| Debt/Equity Ratio | -94.0% |
How did AQS perform over the long term?
See historical performance and comparison